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Pancreatic cancer is almost inevitably associated with progressive
nutritional decline (Wigmore et al, 1997a). Weight-loss in patients
with gastrointestinal cancer is often refractory to therapeutic
intervention and is associated with a shorter survival time and a
reduced quality of life (DeWys et al, 1980; Ovesen et al, 1993a).
The provision of conventional oral nutritional supplements may
increase overall dietary intake but this does not generally lead to
any benefit in terms of nutritional status (Evans et al, 1987;
Ovesen et al, 1993b). Consequently it has been suggested that the
metabolic processes which contribute to weight-loss in patients
with cancer may also block the accretion of lean tissue (Moldawer
and Copeland, 1997).
Pro-inflammatory cytokines, notably interleukin 6 (IL-6), can
induce a cachectic state when injected into animals and mono-
clonal antibodies to such cytokines may attenuate certain features
of cachexia in tumour-bearing animals (McNamara et al, 1992).
The acute phase protein response (APPR) has been shown to be
associated with increased resting energy expenditure (Falconer et
al, 1994a) and to correlate with reduced nutritional intake
(Wigmore et al, 1997b) in weight-losing patients with pancreatic
cancer. In addition, the APPR has been demonstrated to be the
strongest independent predictor of poor prognosis in patients with
pancreatic cancer (Falconer et al, 1995). The APPR is modulated
primarily by pro-inflammatory cytokines, including IL-6
(Heinrich et al, 1990). Thus there appears to be a strong link
between pro-inflammatory cytokine activity and the development
of cachexia in patients with pancreatic cancer. Attempts to manip-
ulate the inflammatory response in cancer patients with the inten-
tion of improving nutritional status have been made previously
with promising results (McMillan et al, 1997).
The n-3 polyunsaturated fatty acids, eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA), are immunomodulatory
and have been shown to suppress endotoxin-induced production
of pro-inflammatory cytokines such as IL-1 and tumour necrosis
factor (TNF) by peripheral blood mononuclear cells (PBMC) from
healthy volunteers (Meydani et al, 1993). Studies of weight-losing
pancreatic cancer patients receiving high-purity EPA have demon-
strated suppression of PBMC IL-6 production (Wigmore et al,
1997c). EPA has also been shown to have inhibitory effects on the
growth of human pancreatic cancer cell lines in vitro (Falconer et
al, 1994b) and to have anti-tumour and anti-cachectic effects in the
chemoresistant murine MAC16 colon adenocarcinoma model
(Beck et al, 1991). The cachexia seen in this animal model has
been attributed to the production of a proteolysis inducing factor
by tumour cells and such a factor is also found in tumour-bearing
humans with cachexia (Todorov et al, 1996). It has been suggested
that EPA may act by inhibiting the end organ effects of this factor
(Tisdale, 1996).
We have previously reported that administration of a mixed fish
oil preparation (providing around 2.2 g EPA and 1.4 g DHA daily)
and a pure EPA preparation (providing 6 g EPA daily) will
stabilize weight in patients with unresectable pancreatic cancer
(Wigmore et al, 1996; Barber et al, 1997). Clearly, in order to lay
down new tissue and thereby increase body weight additional
macronutrients need to be consumed.
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The present study aimed to assess whether the provision of addi-
tional oral calories and protein in conjunction with fish oil could
reverse weight-loss in patients with advanced pancreatic cancer.
MATERIALS AND METHODS
Patients
Patients enrolled were men or non-pregnant, non-lactating women
between 18 and 80 years with histological confirmation or
unequivocal operative or radiological diagnosis of unresectable
adenocarcinoma of the pancreas with evidence of ongoing weight-
loss. Patients had a life expectancy of over 2 months and a WHO
performance status † 2 at enrolment. Written, informed consent
was obtained from all patients. Patients were excluded if they had
received surgery or endoscopic stenting during the previous 4
weeks, had other active medical conditions, another malignancy or
were receiving medication which could profoundly modulate
metabolism or weight. No patients had received radiotherapy
or chemotherapy. The study protocol was approved by the Lothian
Ethical Committee. A total of 20 patients were recruited to the
study. Confirmation of unresectable pancreatic adenocarcinoma
was by histology (16/20) or unequivocal operative or radiological
findings (4/20). Seventeen patients had cancers of the head of
pancreas and three of the body. On enrolment, none of the patients
were jaundiced, pyrexial, ascitic, severely anaemic or had clinical
or radiological evidence of infection and none were taking steroid
drugs. All patients had adequate pain control at the time of study.
Pancreatic enzyme supplements were administered if patients had
or developed clinical evidence of steatorrhoea.
Patients were studied formally at baseline and 3 and 7 weeks,
although patients were assessed approximately monthly until
death, withdrawal from the study or until their condition deterio-
rated such that further assessment was not possible. Trial results
were monitored independently.
Fish oil-enriched nutritional supplement
The fish oil-enriched nutritional supplement was provided by Ross
Products Division, Abbott Laboratories, Columbus, Ohio, USA.
The composition of this product is shown in Appendix 1. Patients
were requested to store product in the refrigerator.
Patients were asked to consume two cans per day (providing
610 kcal, 32.2 g protein, 2.2 g EPA and 0.96 g DHA). Compliance
was assessed by a diary of consumption, return of labels from
empty cans and by plasma fatty acid analysis at baseline and after
3 weeks￿ consumption of the supplement.
Toxicity assessment
Blood was drawn for full blood count, electrolytes, urea, glucose
and liver function tests. These were measured using standard auto-
mated techniques in the haematology and clinical chemistry labo-
ratories of the Royal Infirmary, Edinburgh, UK. A history and
full clinical examination was performed at each of these visits.
Toxicity reported to general practitioners or observed on clinical
examination was documented.
Nutritional and metabolic assessment
Anthropometry
At the initial assessment, height, pre-illness stable weight and
duration of weight-loss were recorded. Subjects were weighed on
spring balance scales (Seca, Germany) without shoes and wearing
light clothing. Mid-arm muscle circumference (MAMC) was
calculated using Jelliffe￿s equation (Jelliffe, 1966). Triceps skin-
fold thickness (TSF) was measured using Harpenden calipers
(John Bull British Indicators Ltd, UK). Three measurements were
performed and the mean value recorded.
Body composition analysis
Body composition was measured using a Xitron 4000B multiple
frequency bio-electrical impedence analyser (Xitron Technologies,
San Diego, CA, USA). All assessments were made with the subject
supine and limbs apart. Electrodes were placed over the wrist and
ankle joints and metacarpal and metatarsal heads. Repeat measure-
ments were performed using the same pair of limbs. Resistance was
measured at 200 Hz. Values for total body water were derived using
equations validated in a similar patient group (Hannan et al, 1995).
Lean body mass was calculated assuming that lean tissue contains
73% water (Shizgal, 1990).
Nutritional intake
The daily caloric intake of patients was measured at baseline and
after 3 weeks of supplement administration. Values were based on
the mean intake recorded in a 3-day food diary calculated using
CompEat 4 software (Nutrition Systems, London, UK).
Energy expenditure
At baseline and after 3 weeks resting energy expenditure (REE)
was measured as described previously (Falconer et al, 1994a) after
an overnight fast using a ventilated hood system (Deltatrac II,
Datex, Helsinki, Finland). Patients attended at 08:00 h and rested
for at least 30 min in the supine position. Measurements were
made over at least 30 min with patients supine in a thermoneutral
environment. Measurements for the initial 10 min were discarded
and the remaining values averaged. The equipment was calibrated
before each measurement.
Acute phase protein response
The APPR was documented by assaying serum C-reactive protein
(CRP) (Abbott Diagnostic, Maidenhead, UK). The limit of detec-
tion of this assay is 10 mg l—1.
Fatty acid analysis
Plasma phospholipid fatty acid analysis was performed by gas
chromatography as described previously (Wigmore et al, 1996)
before commencement of the supplement and 3 weeks thereafter.
Performance status and appetite
Karnofsky performance status was noted before commencement
of the supplement, at three weeks and at monthly intervals there-
after. Appetite was measured on a numerical rating scale between
0 and 10, where 0 indicated absolutely no appetite and 10 indi-
cated an extremely good appetite (Simons et al, 1996).
Survival
Survival was recorded from the time of diagnosis and study baseline
to the time of death. Diagnosis was defined as the date of confirma-
tion of adenocarcinoma of the pancreas by histological examination
or of unequivocal operative or radiological findings in patients in
whom definitive pathological confirmation of diagnosis was lacking.Statistical analysis
Data are presented as the median and interquartile range. The
study was analysed on an intention-to-treat basis. Due to the
inevitable deterioration of patients in such a study of a palliative
intervention, of 20 patients initially enrolled, data were available
on 18 patients at 3 weeks and 13 patients at 7 weeks. Paired
comparisons with baseline values were performed using Wilcoxon
signed rank test. A P-value of less than 0.05 was taken to denote
significance.
RESULTS
Patient characteristics
Patients comprised ten males and ten females of median age 62
years (range 51—75). Tumour stages were as follows: stage 2, eight
patients; stage 3, three patients; and stage 4, nine patients. No
patients underwent prior chemotherapy or radiotherapy. Eight
patients underwent non-resectional palliative surgical procedures
and eight patients had endobiliary stenting prior to the study.
Patients had tumours of the pancreatic head in 17 cases and the
pancreatic body in the remainder. Baseline characteristics of
patients is shown in Table 1. Of 20 patients enrolled, 18 were
available for analysis at week 3 and 13 patients at week 7. One
patient on whom data was available at 7 weeks had discontinued
the supplement at week 3 due to excessive weight gain. No
patients on whom data was available over the 7-week study period
developed clinically detectable ascites or oedema.
Tolerance/toxicity
Patients consumed a median of 1.9 cans of the fish oil-enriched
supplement per day (range 1.2—2). Full blood count, electrolytes,
urea, glucose and liver function tests were assessed at each review.
Values did not change significantly over the course of the study
(data not shown).
Two patients developed and one patient had worsening of pre-
existing steatorrhoea with administration of the supplement. This
was successfully treated by pancreatic enzyme supplementation.
Otherwise no patients developed adverse events which would not
be expected with the normal progression of advanced pancreatic
cancer.
At 3 weeks two patients were unavailable for analysis due to
disease progression. At 7 weeks a further five patients were
unavailable due to disease progression. Reasons for stopping the
supplement during the 7-week study period were temporary inter-
ruption in supply in one patient (after 3 weeks), excessive weight
gain in one patient (after 3 weeks), dislike of taste in two patients
(after 3 weeks) and progression of disease in the remainder. Data
were only available for one patient not taking the supplement at 7
weeks. Thus all 18 patients assessed at 3 weeks and 12 of 13
patients assessed at 7 weeks were consuming the supplement.
Body weight
Changes in body weight for individual patients are depicted graph-
ically in Figure 1. Weight change at 3 (n = 18) and 7 (n = 13)
weeks is shown in Table 2. Patients had statistically significant
weight gain at 3 and 7 weeks of median 1 and 2 kg respectively.
The patient who had discontinued the supplement at 3 weeks but
on whom data was available at 7 weeks gained 0.5 kg over the first
3 weeks on the supplement and lost 0.9 kg in the subsequent
4 weeks off the supplement. Not including this patient, median
weight gain at 7 weeks was 2.5 kg (0.2—4.6).
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Table 1 Baseline characteristics of study patients with advanced pancreatic
cancer (n = 20)
Weight (kg) 55.2
(48.8–61.2)
Body mass index (kg m–2) 19.8
(17.8–21.8)
Rate of weight change per month (kg) –2.9
(–4.4––2.2)
Percentage weight loss 17.9
(15.9–22.8)
Mid arm muscle circumference (cm) 20.8
(18.4–22.4)
Triceps skinfold thickness (mm) 11.1
(7.8–15.9)
Percentage total body water 52.9
(51.2–56.1)
Lean body mass (kg) 41.5
(38.1–44.8)
Fat mass (kg) 14.5
(12.3–16.7)
C-reactive protein (mg l–1)1 0
(<10–27)
Karnofsky performance statusa 85
(80–90)
Appetiteb 5
(3–7)
Figures are median (interquartile range). aFrom a score of 10 (moribund) to
100 (normal). bFrom a score of 0 (none) to 10 (excellent).
Table 2 Change in characteristics of patients with advanced pancreatic
cancer after 3 and 7 weeks’ administration of a fish oil-enriched nutritional
supplement.
Duration of supplement 3 weeks 7 weeks
administration
Number of patients 18 13
PP
Weight change (kg) +1.0 0.024 +2.0 0.033
(–0.1 ± 2.0) (–0.4 ± 4.6)
Change in mid arm muscle 0 NS +0.4 NS
circumference (cm) (–0.2 ± 0.5) (–0.7 ± 1.1)
Change in triceps skinfold 0 NS +0.2 NS
thickness (mm) (–0.2 ± 0.4) (–0.5 ± 0.6)
Change in percentage total +0.1 NS –0.1 NS
body water (–0.3 ± 1.9) (–0.4 ± 1.5)
Change in lean body mass +1.0 0.0064 +1.9 0.0047
(kg) (+0.6 ± 1.4) (+1.0 ± 3.0)
Change in fat mass (kg) –0.2 NS +0.2 NS
(–0.8 ± 0.9) (–0.8 ± 2)
Change in C-reactive 0 NS 0 NS
protein (mg/l) (0 ± 3) (–5 ± 22)
Change in Karnofsky +10 0.0047 +10 0.046
performance statusa (0 ± 10) (0 ± 10)
Change in appetiteb +1 0.001 +1 NS
(0 ± 1) (0 ± 1)
Figures are median (interquartile range). aFrom a score of 10 (moribund) to
100 (normal). bFrom a score of 0 (none) to 10 (excellent). Paired comparison
with baseline by Wilcoxon signed rank test.A fish oil-enriched oral supplement in cachexia 83
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Anthropometry and body composition analysis
Values for MAMC and TSF recorded before commencement of
the supplement and changes after 3 and 7 weeks are shown in
Tables 1 and 2. There was no significant change in either MAMC
or TSF over this period.
Values for total body water expressed as a percentage of total
body weight are also presented in Tables 1 and 2. There was no
significant change in this factor in patients remaining in the trial at
3 and 7 weeks.
Values for calculated lean body mass and fat mass are presented
in Tables 1 and 2. There was a statistically significant rise in
calculated lean body mass at 3 and 7 weeks (of median 1.0 kg and
1.9 kg respectively) but no change in fat mass at either time point.
Nutritional intake
The daily caloric intake of patients before commencement of
supplement and after 3 weeks (n = 18) are presented in Table 3.
There was a statistically significant increase in caloric intake after
3 weeks (P = 0.0016). The median increase for each patient was
372 kcal day—1.
Energy expenditure
REE and REE expressed per kg body weight and per kg lean body
mass as measured at baseline and after 3 weeks are presented in
Table 3. While there was no change in overall REE (P = 0.18),
REE kg body weight—1 and REE kg lean body mass—1 both fell
significantly (P = 0.025 and 0.018 respectively).
Acute phase protein response
Values for serum CRP concentration before commencement of the
supplement and changes after 3 and 7 weeks are shown in Tables 1
and 2. There was also no change in the percentage of patients
exhibiting an APPR as defined by a CRP ‡ 10 mg l—1 throughout
the study period.
Fatty acid analysis
The EPA, DHA and arachidonic acid content of plasma phospho-
lipids of patients before commencement of supplement and after 3
weeks are presented in Table 4. There was a statistically signifi-
cant increase in both EPA and DHA in plasma phospholipids after
3 weeks.
Performance status and appetite
Scores for Karnofsky performance status before administration of
the supplement and change after 3 and 7 weeks are shown in
Tables 1 and 2. There was a statistically significant improvement
in Karnofsky performance status compared with baseline after 3
and 7 weeks administration of the supplement (P = 0.0047 and
0.046 respectively).
Appetite scores before administration of the supplement and
change after 3 and 7 weeks are shown in Tables 1 and 2. There
was a statistically significant improvement in appetite at 3 weeks
(P = 0.0095).
Survival
Nineteen of the patients have died. One patient remains alive at 14
months from the time of diagnosis. The survivor has histological
confirmation of the diagnosis of pancreatic adenocarcinoma. The
censored median survival from the time of diagnosis for all patients
was 254 days (124—311). The censored median survival from the
time of commencing the supplement was 170 days (90—270).
Table 3 Caloric intake and resting energy expenditure of 18 patients with advanced pancreatic cancer at baseline and after 3 weeks’ administration of a fish
oil-enriched nutritional supplement
Duration of Caloric intake REE REE/kg body REE/kg lean
supplement (kcal day–1) (kcal day–1) weight body mass
administration (kcal kg–1 day–1) (kcal kg–1 day–1)
0 1450 1339 24.2 34.0
(1048–2043) (1159–1448) (23.1–27.7) (29.6–35.6)
3 weeks 1798a 1303b 24.0c 31.8d
(1355–2474) (1186–1470) (20.2–25.8) (27.7–33.9)
Figures are median (interquartile range). REE, resting energy expenditure. Paired comparison of value at 3 weeks versus baseline using Wilcoxon signed rank
test: aP = 0.0016; bP = 0.18; cP = 0.025; dP = 0.018.
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Figure 1 Weight change of 20 patients with advanced pancreatic cancer
administered a fish oil-enriched nutritional supplement after 3 and 7 weeks.
Median rate of weight loss prior to intervention was 2.9 kg per month. Median
weight gain at 3 weeks was 1.0 kg (P=0.028 vs baseline Wilcoxon signed
rank test). Median weight gain at 7 weeks was 2.0 kg (P=0.033)DISCUSSION
In the present study the administration of a nutritional supplement
enriched with fish oil resulted in weight gain in a group of patients
with advanced pancreatic cancer who had previously been losing
weight at a median rate of 2.9 kg month—1.
Not all of the patients who entered the present study completed
the 7-week study period. This is a reflection of the advanced stage
at presentation and subsequent poor survival of patients with
pancreatic cancer. By observing weight change in those survivors
who remained on study at 3 (n = 18/20) and 7 (n = 13/20) weeks
there might be a bias to overestimate the overall efficacy of EPA as
an anti-cachectic agent. Nevertheless, the finding of weight gain in
the majority of patients at both time points contrasts markedly with
our previous study of patients receiving supportive care alone
which demonstrated near uniform progressive weight loss in
patients with this disease (Wigmore et al, 1997a). In addition,
previous controlled trials of oral nutritional supplementation in
patients with advanced cancer have succeeded in increasing nutri-
tional intake but have not been able to show any change in weight
change compared with controls (Evans et al, 1987; Ovesen et al,
1993b). There was a variation in response of patients in the present
study with some continuing to lose weight. The factors determining
response are not clear as there was no relationship between weight
change and disease stage, previous surgery or the acute phase
response. Such analysis is complicated by the fact that even patients
who continued to lose weight experienced a slowing of their rate of
weight loss with the administration of the trial supplement.
It has been reported that increased body weight following
parenteral and enteral nutritional support in cancer patients is
largely due to the accumulation of body water (Cohn et al, 1982).
However, in the present study there was no change in hydration as
total body water as a percentage of body weight remained stable.
Values for lean body mass and fat mass were derived from bioi-
mpedence measurements. Overall there was a small but statisti-
cally significant increase in lean body mass with administration of
the supplement while fat mass remained stable. The coefficient of
variation for the estimate of lean body mass has been estimated to
be around 2 kg (Jensen et al, 1997). Most of the changes docu-
mented in this study were around this value and therefore the inter-
pretation of data on individual patients is difficult. Nevertheless,
the changes for the group as a whole suggest that patients were
laying down lean tissue rather than fat to account for weight gain
and this may have contributed to the observed rise in Karnofsky
performance status. This contrasts with studies of synthetic
progestogens such as medroxyprogesterone acetate and megestrol
acetate in similar patients in whom weight gain is due to the
accumulation of fat (Loprinzi et al, 1993; Simons et al, 1998).
Measurements of MAMC and TSF demonstrated no significant
change from baseline levels but this is not surprising given the
small changes in bioimpedence-derived body composition seen.
However, they do provide supporting evidence that protein and fat
reserves were at least stabilized with administration of the fish oil-
enriched supplement. This is in contrast to the continuing decline
in MAMC and TSF seen in similar patients who undergo no
specific intervention (Wigmore et al, 1997a).
Patients in this study achieved a significant increase in nutri-
tional intake and a relative fall in resting energy expenditure.
Patients did not simply replace normal food intake with the
supplement provided. Overall, patients had an improvement in
energy balance of around 500 kcal per day. This is entirely
compatible with the weight gain seen and may have provided addi-
tional energy for activities of daily living, reflected in the observed
improvements in Karnofsky performance status. Appetite
appeared to increase over the early part of the study period and
may account for the overall increase in food intake.
The fish oil-enriched nutritional supplement was well tolerated
with all patients able to consume over one can (237 ml) per day
and 15 of 18 managing over 1.75 cans per day. The only adverse
event attributable to the trial preparation was steatorrhoea in
two patients. A further patient described worsening of their pre-
existing steatorrhoea. Steatorrhoea is common in patients with
advanced pancreatic cancer (Perez et al, 1983).
There was a marked rise in levels of EPA and DHA in plasma
phospholipids representing 5.2% and 4.8% respectively of fatty
acids after 3 weeks of receiving the supplement. This also
provided an objective measure of patient compliance. Such a
pattern of change is similar to that previously reported following
fish oil supplementation (Leaf and Weber, 1988; Wigmore et al,
1996). The percentage of EPA incorporation achieved is similar to
that seen after supplementation with crude fish oil capsules in
pancreatic cancer patients given a similar final dose equivalent to
2 g EPA day—1 after a dose escalation period (Wigmore et al, 1996).
We have previously demonstrated down-regulation of pro-
inflammatory cytokine release and C-reactive protein concentra-
tions following the administration of EPA for 1 month (Wigmore
et al, 1997c). CRP may be used as a marker for pro-inflammatory
cytokine activity in vivo. In the present cohort of patients, the
proportion with an elevated CRP remained stable throughout
the study period. In patients with advanced pancreatic cancer
receiving no specific intervention, CRP tends to rise with disease
progression (Falconer et al, 1994a). The provision of fish oil
supplementation provided by the trial supplement in the current
study may have prevented this progressive rise in CRP. A prospec-
tive randomized trial would be required to address this issue more
formally.
Polyunsaturated fatty acids such as EPA have been shown to
have an inhibitory effect on human pancreatic carcinoma cell lines
in vitro (Falconer et al, 1994b). These effects may occur via cell
cycle arrest and the induction of apoptosis (Lai et al, 1996). EPA
will also slow the growth of experimental tumours in mice (Beck
et al, 1991) and it is possible that part of the effect upon cachexia
seen in the present study was secondary to inhibition of tumour
growth. However, serial tumour imaging in pancreatic cancer is
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Table 4 Percentage of EPA, DHA and AA in plasma phospholipid profile of
18 patients with advanced pancreatic cancer at baseline and after 3 weeks’
administration of a fish oil-enriched nutritional supplement
Duration of EPA DHA AA
supplement (%) (%) (%)
administration
0 0.5 2.9 6.4
(0.2–1.6) (1.6–3.9) (4.1–7.5)
3 5.2 a 4.8 b 5.1 c
(2.6–6.7) (3.3–5.3) (4.3–6.4)
Figures are median (interquartile range). EPA, eicosapentaenoic acid; DHA,
docosahexaenoic acid; AA, arachidonic acid. Paired comparison of value at
3 weeks versus baseline using Wilcoxon signed rank test: aP = 0.0003; bP =
0.0086; cP = 0.33.difficult to interpret and expensive and was thus not performed.
Overall survival of patients with pancreatic cancer is very poor
with a median of 4.1 months (Ahlgren, 1996). Median survival
from diagnosis in the present study was over 8 months although a
condition of enrolment was that survival was expected to be over 2
months. Similar conditions apply to most chemotherapy trials
where median survival of untreated patients has been noted to be
between 63 and 122 days and overall median survival of treated
patients to be between 160 and 170 days (Fearon et al, 1996).
Clearly, overall survival in this study is at the upper end of that
seen in chemotherapy trials but without the side-effects associated
with chemotherapy. A recent randomized, controlled study of a
mixed fish oil preparation (providing around 3 g of EPA and 2 g of
DHA daily) in a group of patients with advanced cancer has
suggested a modest survival benefit for those patients receiving
fish oil (Gogos et al, 1998).
The present small pilot study suggests that a fish oil-enriched
nutritional supplement has the potential to be a safe, effective anti-
cachectic agent, in contrast to conventional nutritional supple-
ments. A randomized, controlled trial would be required to
confirm the observed anti-cachectic effect, evaluate any effect on
survival and reveal any as yet undetected side-effects. Such a study
is currently underway.
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Appendix 1 Composition of the trial fish oil-enriched nutritional
supplement. Between-batch coefficients of variation in the proportion of EPA
and DHA in the supplement were <1% and <1.5% respectively
Nutrient Amount per can (237 ml)
Energy (kcal) 310
Protein (g) 16.1 (21% of calories)
Carbohydrate (g) 49.7 (61% of calories)
Fat (g) 6.5 (18% of calories)
EPA 1.09
DHA 0.46
Vitamin A (IU) 1320
Vitamin D (IU) 192
Vitamin E (IU) 72
Vitamin K (IU) 32
Vitamin C (mg) 156
Folic acid (µg) 456
Thiamin (mg) 1.6
Riboflavin (mg) 1.2
Vitamin B6 (mg) 1.2
Vitamin B12 (µg) 4.32
Niacin (mg) 9.6
Choline (mg) 126
Biotin (µg) 187
Pantothenic acid (mg) 6
Sodium (mg) 360
Potassium (mg) 480
Chloride (mg) 365
Calcium (mg) 432
Phosphorus (mg) 300
Magnesium (mg) 108
Iodine (µg) 42
Copper (mg) 1.5
Manganese (mg) 0.6
Zinc (mg) 7
Iron (mg) 5.3
Selenium (mg) 22
Chromium (µg) 30
Molybdenum (µg) 49.4